TC Biopharm (Holdings) Plc (TCBPY)
OTCMKTS · Delayed Price · Currency is USD
0.2000
-0.0100 (-4.76%)
Sep 24, 2025, 4:00 PM EDT
TC Biopharm (Holdings) Company Description
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States.
Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers.
The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc
| Country | United Kingdom |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 39 |
| CEO | Bryan Kobel |
Contact Details
Address: Maxim 1 Motherwell, ML1 4WR United Kingdom | |
| Phone | 44 14 1433 7557 |
| Website | tcbiopharm.com |
Stock Details
| Ticker Symbol | TCBPY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bryan Leland Kobel | Chief Executive Officer and Director |
| Martin Edward Thorp | Chief Financial Officer and Director |
| Christopher Camarra | Executive Vice President of Communications |
| Dr. Lauren Bor Ph.D. | Head of Commercial Development Division |